Keyphrases
Patient-specific
100%
Peripheral Arterial Disease
100%
Nilotinib
100%
Pharmacogenomics
100%
Induced Pluripotent Stem Cells (iPSCs)
100%
Specific Susceptibility
15%
In Vitro Model
15%
Chronic Myeloid Leukemia
15%
Efficient System
7%
Clinical Screening
7%
Adverse Drug Reaction
7%
Non-invasive Interventions
7%
Genetic Phenotype
7%
Causal Variants
7%
Adverse Effects
7%
Genetic Screening
7%
Clinical Genetics
7%
Myocardial Infarction
7%
Vascular Smooth muscle Cells
7%
Mechanistic Understanding
7%
Increased Mortality
7%
Inter-individual Variability
7%
Tyrosine Kinase Inhibitor
7%
Genome Editing
7%
United States
7%
Novel Variants
7%
Drug-induced
7%
Gene Response
7%
Amputation
7%
Ischemic Stroke
7%
Myocardial Ischemia
7%
Large Artery Atherosclerosis
7%
Coronary Artery Disease
7%
Risk Factors
7%
Mortality Risk
7%
Induced Phenotype
7%
Medicine and Dentistry
Nilotinib
100%
Pharmacogenomics
100%
Arteriosclerosis Obliterans
100%
Side Effect
15%
In Vitro
15%
Chronic Myelogenous Leukemia
15%
Atherosclerosis
15%
Amputation
7%
Vascular Smooth Muscle Cell
7%
Tyrosine-Kinase Inhibitor
7%
Brain Ischemia
7%
Clinical Genetics
7%
Genome Editing
7%
Ischemic Heart Disease
7%
Gene Expression
7%
Genetic Screening
7%
Adverse Event
7%
Myocardial Infarction
7%
Adverse Drug Reaction
7%
Induced Pluripotent Stem Cell
7%
Pharmacology, Toxicology and Pharmaceutical Science
Peripheral Occlusive Artery Disease
100%
Nilotinib
100%
Pharmacogenomics
100%
Chronic Myeloid Leukemia
15%
Side Effect
15%
Atherosclerosis
15%
Adverse Drug Reaction
7%
Protein Tyrosine Kinase Inhibitor
7%
Brain Ischemia
7%
Heart Infarction
7%
Adverse Event
7%
Ischemic Heart Disease
7%